Watchman Laa denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for watchman laa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Issue a "Not FDA-Approved" Denial for the Watchman LAA Closure Device

The Watchman device holds FDA approval for use in patients with non-valvular atrial fibrillation to reduce stroke risk as an alternative to anticoagulation therapy. A "not FDA-approved" denial from Cigna is therefore surprising on its face — but it can arise in specific circumstances: the procedure was coded incorrectly; the claim was submitted for a patient population, anatomical indication, or procedural variation that Cigna's reviewer interpreted as outside the cleared label; or the denial reflects an administrative error or outdated internal policy that has not been updated to reflect the device's current FDA status.

## Why This Denial Is Appealable

Because FDA approval of the Watchman is a matter of public regulatory record, this type of denial is among the most straightforward to appeal. The primary task is to demonstrate that the procedure performed matches the FDA-approved indication and labeling. If the denial is an administrative error, a peer-to-peer call between the cardiologist and Cigna's medical director may resolve it before a formal appeal is necessary.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): Submit within the deadline on the denial notice. Include the FDA approval documentation as a primary exhibit.
• External review (ACA §2719): After final internal denial, request IRO review. IROs are required to assess coverage against objective clinical standards, not just insurer policy. The external review window is approximately four months from the final internal denial.
• Expedited review: Request if clinical urgency supports it (e.g., ongoing anticoagulation risk while the device implant is pending payment resolution).

## Documentation to Gather

1. FDA clearance documentation: The FDA's 510(k) clearance summary or PMA approval for the Watchman device — this directly refutes the denial's premise. 2. Procedure and indication match: Chart documentation confirming the patient's diagnosis of non-valvular atrial fibrillation and that the procedure was performed for the approved indication. 3. Operative and procedural report: The procedural report confirming the device used and the indication documented at the time of the procedure. 4. Prescriber letter: The performing cardiologist or electrophysiologist should write a letter directly addressing Cigna's "not FDA-approved" characterization, attaching the FDA documentation and confirming that the procedure was performed within the cleared indication.

## Criteria-Mapping Structure

Obtain the specific Cigna coverage policy and denial rationale. Map each stated reason for denial to either the FDA approval record or the patient's chart. If the denial was triggered by a procedure code mismatch, correct the code and resubmit alongside the appeal. Present both the corrected claim and the substantive appeal simultaneously to close the loop.